Centessa Competitors
| CNTA Stock | USD 24.73 0.02 0.08% |
Centessa Pharmaceuticals vs Dyne Therapeutics Correlation
Poor diversification
The correlation between Centessa Pharmaceuticals PLC and DYN is 0.74 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Centessa Pharmaceuticals PLC and DYN in the same portfolio, assuming nothing else is changed.
Moving against Centessa Stock
| 0.68 | DRTS | Alpha Tau Medical | PairCorr |
| 0.63 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.51 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.51 | EQ | Equillium | PairCorr |
| 0.51 | VALN | Valneva SE ADR | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Centessa Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Centessa Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Centessa Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Centessa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Centessa Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Centessa Stock performing well and Centessa Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Centessa Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| APGE | 2.17 | 0.26 | 0.08 | 0.34 | 2.86 | 5.32 | 23.21 | |||
| XENE | 1.63 | 0.10 | 0.03 | 0.31 | 1.83 | 3.78 | 10.56 | |||
| AAPG | 2.65 | (0.43) | 0.00 | (1.37) | 0.00 | 5.25 | 16.72 | |||
| RARE | 3.14 | (0.51) | 0.00 | (0.27) | 0.00 | 7.73 | 51.23 | |||
| CELC | 2.24 | 0.47 | 0.19 | 1.01 | 2.07 | 5.87 | 17.89 | |||
| ZLAB | 1.99 | (0.15) | 0.00 | (0.19) | 0.00 | 6.01 | 10.32 | |||
| CGON | 2.94 | 0.40 | 0.14 | 0.44 | 2.55 | 5.15 | 34.61 | |||
| SLNO | 2.56 | (0.37) | 0.00 | (0.21) | 0.00 | 5.16 | 15.78 | |||
| LEGN | 2.48 | (0.85) | 0.00 | (6.66) | 0.00 | 3.97 | 19.65 | |||
| DYN | 3.10 | (0.22) | 0.00 | (0.28) | 0.00 | 7.01 | 26.40 |
Cross Equities Net Income Analysis
Compare Centessa Pharmaceuticals and related stocks such as Apogee Therapeutics, Xenon Pharmaceuticals, and Ascentage Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (575 M) | (546.2 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| DYN | 264 M | (1.6 B) | 87 M | (356 M) | (67 M) | 50 M | (1.2 B) | 76 M | (4.8 M) | (13.5 M) | (58.7 M) | (149.3 M) | (165.2 M) | (235.9 M) | (317.4 M) | (365 M) | (383.3 M) |
Centessa Pharmaceuticals and related stocks such as Apogee Therapeutics, Xenon Pharmaceuticals, and Ascentage Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Centessa Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Centessa Pharmaceuticals PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Centessa Pharmaceuticals Competitive Analysis
The better you understand Centessa Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Centessa Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Centessa Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Centessa Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Centessa Pharmaceuticals Competition
Centessa Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Centessa Pharmaceuticals in relation to its competition. Centessa Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Centessa Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Centessa Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Centessa Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Centessa Pharmaceuticals position
In addition to having Centessa Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Centessa Pharmaceuticals Correlation with its peers. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. Projected growth potential of Centessa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Centessa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Centessa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Centessa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Centessa Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.